Changda International Holdings receives first commercial order for Thiophene from Sanofi Aventis

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Dec 1 2009

Changda International Holdings (OTCBB: CIHD), the Weifang based specialty chemicals manufacturer has received a first commercial order for it product Thiophene from Sanofi Aventis (NYSE: SNY), the French pharmaceutical multinational. The order was preceded by a rigid due diligence process undertaken by Sanofi on Changda International and its products.

“This development emphasizes our high quality standards and ability to compete on an international level and is a further milestone for our company. It is a further demonstration of how our R&D, product development and market intelligence work together to successfully conquer new markets with new products,” said Mr QinRan Zhu, CEO of the company.

Source:

http://www.changdastock.com/

Posted in: Pharmaceutical News

Tags: ,

Comments (0)

Suggested Reading

Hundreds of chemicals linked to breast cancer risk identified in new study
Piquin chili's health benefits spotlighted due to high antioxidant content
Vaccines targeting chronic diseases show promise in combatting age-related conditions
Study unveils novel bladder cancer diagnostic model based on key mitochondrial genes
Study reveals skin bacteria removal boosts brain attention signals
Study links cord blood lipid levels to early ADHD and autism symptoms
Household chemicals endanger brain's myelin-forming cells
Prenatal exposure to phthalates linked to higher risk of preterm birth and low birth weight

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Microfluidic chips advance neurodegenerative disease research